

## 22nd Annual Oncology Research & Education Day

*Co-Chairs: Lorin Dodbiba MD FRCPC and Len Luyt PhD*

Ronald D. Schmeichel Building for Entrepreneurship and Innovation, Western University

Thursday, June 18, 2026



8:00 AM – 4:30 PM

### Overall Learning Objectives:

**By the end of this program, participants will be able to:**

1. To review new contributions from medical oncology, radiation oncology, surgery, and medical biophysics, as well as advanced comprehensive cancer care;
2. Discuss and assess cutting-edge research in oncology, including novel methodologies for studying cancer at the cellular/molecular level and the implications for treatment and patient care;
3. Appraise research findings and demonstrate how collaboration can bridge clinical and basic science research in oncology.

## AGENDA

8:00 – 9:00	<b>REGISTRATION AND OPENING REMARKS - Room: SEI 1110</b>
 8:00	<b>Registration and Refreshments (Coffee/Tea)</b> Please register and enjoy refreshments while networking with colleagues
8:30	<b>Welcome and Opening Remarks</b> Lorin Dodbiba MD FRCPC and Len Luyt PhD - Conference Co-Chairs Michael Ott MD FRCSC - Department of Oncology Chair and Physician Executive Oncology LHSC
8:45 – 9:45	<b>MORNING ORAL PRESENTATIONS - Room: SEI 1110</b> <i>Judges: Glenn Bauman MD FRCPC, Peter J. H. Scott PhD, and Silvia Penuela PhD</i>
8:45	1. Natasha Bruce MSc. Can. - Evaluation of novel OICR38964 inhibitor compound as a therapeutic agent for ovarian cancer.
9:00	2. Shahin Ghaseminejad CAMPED-PhD Can. - A Radiobiological Framework for Precision Dosing in Theranostics: Maximizing Tumor Control, Minimizing Healthy Tissue Damage.
9:15	3. Elena Tay RN Can. - Atypical acute toxicities of weekly docetaxel with radiation (RT) for cisplatin-ineligible patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
9:30	4. Huilin Niu PhD Can. - Converging Path to Metastasis: Stem-like and Proliferative States in Primary Tumours of Myxoid Liposarcoma Leads to Metastatic Progression.
9:45 – 11:45	<b>POSTER AND NETWORKING SESSION (non-CPD activity) - Poster Rooms: SEI 4105 &amp; 4106</b> <i>Refreshments and Snacks: Adjacent to Poster Rooms</i>
 11:45 – 12:15	<b>TALK: The Evolving Landscape of Theranostics in London and Canada (Room: SEI 1110)</b> Michael S. Kovacs PhD – Imaging Program Leader, Lawson Research Institute at St. Joseph’s Health Care London Ryan MacDonald MBA, CHE, BSc, MRT(NM) – Director, Medical Imaging, London Health Sciences Centre Mina Swiha MBBCh, PhD, FRCPC, ABNM – Clinician, Molecular Imaging & Theranostics Stephen Nelli MBA, CHE, BSc. MRT (N) – Director, Medical Imaging & Breast Care, St. Joseph’s Health Care London  <b>Objectives: By the end of this session, participants will be able to describe the current theranostics and imaging programs operating in London; participants will appraise the translational nature of theranostics activities in London including imaging; participants will be able to infer the role of London scientist and clinicians in the implementation of theranostics in Canada.</b>



Morning Evaluation Form



Afternoon Evaluation Form

12:15 – 1:15	<p><b>KEYNOTE LECTURE – Room: SEI 1110</b></p> <p><b>Theranostics – New Developments in Precision Cancer Care that are Transforming Patient Prognosis</b></p> <p><b>Peter J. H. Scott PhD</b></p> <p>Paul L. Carson Collegiate Professor, Radiology   Associate Chair, Basic Science Research   Director, PET Chemistry   Director, Center for Positron Emission Tomography, University of Michigan</p> <p>Objectives: Summarize the history of theranostics that defined the field today; List the theranostics approved by FDA for treatment of neuroendocrine tumors and metastatic prostate cancer; Describe emerging theranostics that are in advanced clinical trials around the world; Demonstrate how dosimetry and theranostics can be applied in personalized cancer care.</p>
1:15– 2:15	<p><b>Lunch - Room: SEI 1110</b></p> 
2:15 –3:15	<p><b>AFTERNOON ORAL PRESENTATIONS - Room: SEI 1110</b></p> <p>Judges: Drs. Glenn Bauman, Peter J. H. Scott, and Silvia Penuela</p>
2:15	5. Oneeb Hassan PhD Can. - Examining the role of a pancreas-specific isoform of SPCA2 in pancreatic pathology.
2:30	6. Fatima Santillan Espinoza PhD Can. - Cyclic Peptide Nanotubes for prostate cancer Imaging.
2:45	7. Sumiya Lodhi PGY2 Resident - Targeted Treatment of Solid Tumors with BRAF Fusions: A Systematic Review.
3:00	8. Anayra de Fatima Goncalves Santiago PhD Can. - NF1-Ras/Raf/MEK Signaling is associated With Immune Cell Infiltration in Locally Advanced Triple-Negative Breast Cancer.
3:15 – 3:45	<p><b>PANEL DISCUSSION: Experimental Agents for the Future - Room: SEI 1110</b></p> <p>Ricardo Fernandes MD - Medical Oncologist and Fellowship Director David Laidley MD - Molecular Imaging and Theranostics Physician Jacques Raphael MD - Medical Oncologist and Director, Baines Centre Peter J. H. Scott PhD - Chemist and Radiochemist Lorin Dodbiba MD – Moderator</p> <p>Objectives: By the end of this session, participants will be able to describe the future of cancer therapeutics; Participants will be able to differentiate between various novel experimental agents; and participants will be able to critique the various approaches being investigated for cancer therapy including imaging.</p>
3:45 – 4:30	<p><b>Award Ceremony - Room SEI 1110</b></p>
3:45	<p><b>Presentation of Awards</b></p> <p>Michael Ott MD - Department of Oncology, Excellence in Academic and Teaching Awards (5) Glenn Bauman MD – Centre for Translational Cancer Research, Trainee Excellence Award (2) Morgan Black - Denise Power Cancer Research Staff Award of Excellence Lorin Dodbiba MD and Len Luyt PhD - Oral and Poster Presentation Awards</p>
4:30	<p><b>Concluding Remarks</b></p> <p>Lorin Dodbiba MD and Len Luyt PhD</p>

\*25% of this program is dedicated to participant's interaction.

\*This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of 4.00 hours (credits are automatically calculated).

\*This program has received an educational grant or in-kind support from: Gold Sponsors: AstraZeneca, Johnson and Johnson Innovative Medicine, Knight Therapeutics, and Novartis. Silver Sponsors: AbbVie, Astellas, Bayer, BeOne Medicines (Canada), Bristol Myers Squibb, Daiichi Sankyo/AstraZeneca, Eisai, EMD Serono, GSK, Ipsen, Lilly, Medison Pharma, Merck, Pfizer. Bronze Sponsors: Roche, Servier, Takeda



**Morning Evaluation Form**



**Afternoon Evaluation Form**